Barry Iacopetta
Overview
Explore the profile of Barry Iacopetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller T, McCoy M, Hemmings C, Iacopetta B, Platell C
Oncol Lett
. 2018 Nov;
16(5):5761-5768.
PMID: 30405752
Immunoediting is defined as a process whereby tumour cells develop the capacity to escape immune cell recognition. Accumulating evidence suggests that cancer stem-like cells (CSCs) have an enhanced capacity to...
2.
Soo R, Chen Z, Yan Teng R, Tan H, Iacopetta B, Tai B, et al.
Oncotarget
. 2018 Jun;
9(37):24801-24820.
PMID: 29872507
Background: Tumor-associated immune cells are prognostic in non-small cell lung cancer (NSCLC) but findings have been conflicting. Objectives: To determine the prognostic role of immune cells according to localization in...
3.
Giardina T, Robinson C, Grieu-Iacopetta F, Millward M, Iacopetta B, Spagnolo D, et al.
Pathology
. 2018 May;
50(4):389-401.
PMID: 29752127
The introduction of next generation sequencing (NGS) in the routine diagnostic setting is still in the development phase and has been limited by its complexity. Targeted NGS offers an attractive...
4.
Zardavas D, Te Marvelde L, Milne R, Fumagalli D, Fountzilas G, Kotoula V, et al.
J Clin Oncol
. 2018 Feb;
36(10):981-990.
PMID: 29470143
Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient...
5.
Soo R, Lim J, Asuncion B, Fazreen Z, Herrera M, Omar M, et al.
Oncotarget
. 2018 Feb;
9(6):6841-6851.
PMID: 29467933
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentially predictive of clinical outcome. The aim of this study was to assess the concordance of reported PD-L1 IHC...
6.
Koh K, Tan G, Low S, Omar M, Han M, Iacopetta B, et al.
Oncotarget
. 2018 Jan;
8(66):110133-110144.
PMID: 29299135
Acquired resistance (AQR) to drug treatment occurs frequently in cancer patients and remains an impediment to successful therapy. The aim of this study was to gain insight into how AQR...
7.
Alqahtani M, Edwards C, Buzzacott N, Carpenter K, Alsaleh K, Alsheikh A, et al.
Fam Cancer
. 2017 Jun;
17(2):197-203.
PMID: 28643016
Individuals with Lynch syndrome (LS) have germline variants in DNA mismatch repair (MMR) genes that confer a greatly increased risk of colorectal cancer (CRC), often at a young age. Identification...
8.
Alqahtani M, Grieu F, Carrello A, Amanuel B, Mashour M, Alattas R, et al.
Asian Pac J Cancer Prev
. 2016 May;
17(4):1917-23.
PMID: 27221876
Background: Lynch Syndrome (LS) is a familial cancer condition caused by germline mutations in DNA mismatch repair genes. Individuals with LS have a greatly increased risk of developing colorectal cancer...
9.
Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene M, Wanherdrick K, et al.
J Med Genet
. 2016 Feb;
53(6):377-84.
PMID: 26831756
Background: Every colorectal cancer (CRC) patient should be tested for microsatellite instability (MSI, a marker for defective DNA mismatch repair) as a first screen for Lynch syndrome (LS). In this...
10.
Leslie C, Bowyer S, White A, Grieu-Iacopetta F, Trevenen M, Iacopetta B, et al.
Pathology
. 2015 Aug;
47(6):557-63.
PMID: 26308130
Tumour infiltrating lymphocytes in primary melanoma have been found to correlate with patient outcomes. A subpopulation of tumour infiltrating lymphocytes expresses the transcription factor forkhead box protein 3 (FOXP3). These...